|
Effect
|
Estimate
|
Standard error
|
p value
|
|---|
|
Dexmedetomidine, per μg/kg/h increase
|
− 0.165
|
0.071
|
0.02
|
|
Age, per year increase
|
− 0.003
|
0.003
|
0.38
|
|
Baseline log NEq/MAP, per unit increase
|
0.312
|
0.059
|
< 0.001
|
|
Location
|
|
Switzerland
|
− 0.672
|
0.101
|
< 0.001
|
|
Australia
|
0
| | |
|
No hydrocortisone
|
0.134
|
0.108
|
0.22
|
|
hydrocortisone
|
0
| | |
|
No CRRT
|
− 0.635
|
0.105
|
< 0.001
|
|
CRRT
|
0
| | |
|
No liver cirrhosis
|
− 1.371
|
0.247
|
< 0.001
|
|
Liver cirrhosis
|
0
| | |
|
No portal hypertension
|
− 0.477
|
0.174
|
0.008
|
|
Portal hypertension
|
0
| | |
|
APACHE III admission diagnosis
|
|
Cardiovascular
|
0.678
|
0.272
|
0.02
|
|
Gastrointestinal
|
0.186
|
0.125
|
0.14
|
|
Hematological
|
0.091
|
0.696
|
0.90
|
|
Musculoskeletal
|
− 0.286
|
0.365
|
0.44
|
|
Renal
|
2.399
|
0.317
|
< 0.001
|
|
Respiratory
|
0.086
|
0.111
|
0.44
|
|
Sepsis
|
0
| | |
- Adjusted for admission diagnosis, hospital site, baseline NEq/MAP ratio, continuous renal replacement therapy, age, administration of hydrocortisone, and presence of liver cirrhosis
- APACHE Acute Physiology And Chronic Health Evaluation, CRRT continuous renal replacement therapy, MAP mean arterial pressure, NEq noradrenaline equivalents, NEq/MAP noradrenaline equivalents to MAP ratio (a higher ratio indicates higher vasopressor need to maintain a certain MAP)
